The nation of Zimbabwe has declined a significant US healthcare agreement valued at 367 million US dollars (272 million pounds) over five years due to the United States' request for sensitive biological samples.
This rejection came to light following a government memo dated December was leaked, revealing that President Emmerson Mnangagwa felt the deal was "skewed".
An official spokesperson has since clarified that the US was demanding access to biological samples for scientific study and commercial purposes but refused to guarantee the benefits from future medical innovations.
"We must now begin the difficult and regrettable process of winding down our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has urged continued talks to find a deal agreeable to both sides so the nation's vital HIV programme can proceed.
Broader Implications
This rejection follows a similar case in Kenya, where a court suspended a related health funding agreement after concerns were filed about the safety of citizens' medical information.
Since returning to office recently, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed aid for the US government, but Trump claimed its spending was "inefficient" and his government was pursuing government-to-government agreements to boost openness and accountability.
Based on reports, 16 nations in Africa have so far agreed to these new health pacts, representing more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this cooperation would have delivered significant benefits for the people of Zimbabwe, especially the 1.2 million presently on antiretroviral therapy via US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any equivalent promise of access to any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that shared data," his statement read.
"Put simply, our country would provide the basic resources for scientific discovery with no certainty that the final treatments would be accessible to our people should a new disease outbreak arise."
Sovereignty and Global Health
He also said that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were upending structures previously set up through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to manage future global health emergencies.
"This mechanism is intended to guarantee that when a country provides its samples, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the resources to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," he added.
"We encourage further dialogue with our US partners on how subsequent collaboration could be arranged in a manner that honours the independence and interests of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but recommended that talks need to persist considering a large portion of the nation's HIV programmes relied on external financing.
"In cases where specific concerns arise, such as those relating to information security or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," it added.
This impasse highlights the continuing tensions between receiving much-needed foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.